Can I Take Vitamin B6 with Low-Dose Naltrexone?

Naltrexone is an opioid receptor antagonist. At its FDA-approved doses (50 mg tablets, or a 380 mg monthly injection sold as Vivitrol) it is used for opioid use disorder and alcohol use disorder. Low-dose naltrexone (LDN), typically 1.5 to 4.5 mg taken at night, is a different clinical use case entirely: it is not an FDA-approved formulation or dose, it is prepared by compounding pharmacies, and it is prescribed off-label for conditions such as fibromyalgia, Crohn's disease, and other autoimmune or chronic inflammatory conditions. Vitamin B6 (pyridoxine and its related forms) is a water-soluble vitamin available in food, standard multivitamins, and high-dose stand-alone supplements.

The core, quotable answer: standard-dose vitamin B6 (food sources and typical multivitamins, generally under 10 mg per day) has no documented pharmacokinetic or pharmacodynamic interaction with compounded low-dose naltrexone, according to the NIH Office of Dietary Supplements' description of B6 metabolism and the absence of any published interaction study between the two agents. The safety concern that does exist, high-dose B6 causing peripheral neuropathy, is a risk of vitamin B6 itself and would occur with or without naltrexone in the picture. Anyone combining LDN with a B6 supplement above the low tens of milligrams per day should discuss total daily B6 intake with their prescriber, because the populations who take LDN often already have neurological symptoms that could mask or be confused with early B6 toxicity.

Is there a real drug-nutrient interaction here?

The honest answer is that this is not really an interaction question. Naltrexone is metabolized hepatically to 6-beta-naltrexol and cleared renally. Vitamin B6 is phosphorylated to pyridoxal-5-phosphate (PLP), used as a coenzyme in amino acid and neurotransmitter metabolism, and excreted as pyridoxic acid. No published data describe B6 altering naltrexone's clearance, or naltrexone altering B6 absorption or activation. That absence of evidence is itself informative: if a clinically meaningful interaction existed at ordinary supplement doses, it would be a reasonably conspicuous finding given how commonly LDN patients also take multivitamins, and no such signal has surfaced in the literature we reviewed.

What deserves attention instead is a coincidence of populations, not a molecular interaction. LDN is most often prescribed for fibromyalgia, Crohn's disease, multiple sclerosis, and other conditions with a neurological or neuroinflammatory component. High-dose vitamin B6 causes a sensory peripheral neuropathy that can look similar to symptoms these patients may already have. That overlap can complicate, not compound, cause-and-effect thinking. It is a diagnostic confounder more than a pharmacological hazard.

What is the dose threshold that actually matters?

Vitamin B6 toxicity is dose- and duration-dependent, and regulators disagree somewhat on where the safety line sits.

• The NIH Office of Dietary Supplements lists a U.S. tolerable upper intake level (UL) of 100 mg per day for adults, based on the Institute of Medicine's 1998 review, and identifies peripheral neuropathy as the primary concern with excess intake (NIH ODS, Vitamin B6 Fact Sheet).
• The European Food Safety Authority's 2023 scientific opinion set a considerably more conservative adult UL of 12.5 mg per day, citing case reports of neuropathy at intakes below the older 100 mg threshold (EFSA, 2023).

These two numbers are not a contradiction to resolve, they reflect different risk tolerances applied to an overlapping but incomplete evidence base of case reports rather than large controlled trials. A practical reading is that food-level intake (roughly 1 to 2 mg per day) and most standard multivitamins (2 to 10 mg per day) sit comfortably under either threshold. Once a supplement regimen pushes total daily B6 into the tens of milligrams, a reader is inside the gap between the two regulatory positions, and once it crosses roughly 50 mg per day sustained over months, published case reports of sensory neuropathy become the operative concern, independent of any other medication.

Does LDN's mechanism have anything to do with B6 at all?

Not directly. LDN's proposed mechanisms are transient opioid receptor blockade followed by receptor-rebound upregulation of endogenous opioid tone, and modulation of glial Toll-like receptor 4 (TLR4) signaling, which researchers hypothesize reduces neuroinflammatory cytokine output. Vitamin B6, as PLP, is a cofactor for synthesizing serotonin, dopamine, and GABA, and for general amino acid transamination. These are separate biochemical systems. It is biologically plausible, but unproven, that adequate B6 status supports the neurotransmitter environment relevant to some of LDN's proposed effects. No trial has tested B6 supplementation as a variable in an LDN treatment protocol, so this remains speculation rather than a claim a reader should act on.

Clinical trial evidence for LDN itself in fibromyalgia, Crohn's disease, and multiple sclerosis exists, but the specific effect sizes reported in small pilot studies should be treated with caution pending a check against the primary literature; this article does not carry forward specific percentage or p-value claims from those trials because they could not be independently verified against a specific paper for this review. If a precise effect size matters to your decision, ask your prescriber for the original trial reference rather than relying on secondhand figures.

When would higher-dose B6 ever be appropriate alongside LDN?

There are a small number of legitimate clinical scenarios where a prescriber deliberately uses B6 above typical multivitamin levels:

• Isoniazid (INH), used for tuberculosis, depletes B6 and is a well-recognized reason to co-prescribe supplemental pyridoxine, generally in the range of 25 to 50 mg per day, to prevent INH-induced neuropathy.
• Cycloserine and hydralazine share a similar B6-antagonist mechanism and can carry a similar rationale for supplementation.
• Rare pyridoxine-responsive conditions, such as certain sideroblastic anemias or homocystinuria, use much higher doses under specialist supervision.

None of these are indications created by LDN itself. If you are on LDN and also on one of these medications, B6 dosing should be managed by whichever prescriber is treating the condition that requires it, with the LDN prescriber informed.

What should you actually watch for?

Routine blood testing for B6 status is not standard unless intake exceeds roughly 50 mg per day or neurological symptoms appear. The relevant lab, when it is indicated, is fasting plasma pyridoxal-5-phosphate (PLP), with a typical adult reference range of approximately 20 to 125 nmol/L, though toxicity correlates more with total dose and duration than with a single lab value.

Symptoms worth reporting to a prescriber promptly, in anyone taking supplemental B6:

• Tingling, burning, or numbness in the hands, feet, or around the mouth
• New unsteadiness or balance problems
• Altered sensitivity to touch or temperature in the extremities
• Distal muscle weakness (fingers or toes)

Because these symptoms overlap with what fibromyalgia, autoimmune neuropathy, or multiple sclerosis can already produce, a new or worsening symptom while on both LDN and a B6 supplement deserves a direct conversation about total daily B6 intake, not an assumption that it is disease progression, and not an assumption that it is the LDN.

Evidence-status interaction assessment

What this does not establish

This article does not establish that vitamin B6, at any dose, meaningfully changes how LDN works, nor that LDN changes how the body handles B6. It also does not establish a safe upper bound that applies to every reader: the NIH and EFSA thresholds differ by a factor of eight, reflecting genuine uncertainty in the underlying case-report evidence rather than a settled number. Anyone with pre-existing peripheral neuropathy, an autoimmune diagnosis, or a prescribed reason for high-dose B6 should treat dosing decisions as something to work out with a prescriber or pharmacist rather than inferring from population-level thresholds.

Practical steps

1. Add up your total daily B6 intake across every supplement and multivitamin you take. Labels list B6 per serving, and people are frequently unaware their combined intake is higher than they assumed.
2. If your combined supplemental B6 is under 10 mg per day, no special action is needed beyond normal awareness.
3. If it is between 10 and 50 mg per day, mention it at your next LDN check-in, especially if you have any baseline neurological symptoms.
4. If it is above 50 mg per day for any reason, discuss the rationale and duration with your prescriber before continuing both agents.
5. There is no established need to separate LDN and B6 by time of day. LDN is commonly dosed at bedtime for reasons unrelated to B6 absorption.